PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

Core Insights - NeuroSense Therapeutics is set to present long-term survival data from its Phase 2b PARADIGM trial of PrimeC for ALS at a scientific conference on March 9, 2026, highlighting a significant 65% reduction in risk of death and a median survival benefit of over 14 months [1][2] Company Overview - NeuroSense Therapeutics is a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's [1] - The company aims to address significant unmet medical needs in neurodegenerative diseases, which currently have limited effective therapeutic options [1] Product Information - PrimeC is NeuroSense's lead drug candidate, an extended-release oral formulation combining two FDA-approved drugs: ciprofloxacin and celecoxib, designed to target multiple mechanisms involved in ALS and Alzheimer's disease [1] - The Phase 2b PARADIGM trial involved 68 ALS patients, demonstrating statistically significant slowing of disease progression and a favorable safety profile over 18 months [1] Clinical Trial Results - The survival analysis from the PARADIGM trial showed a hazard ratio of 0.35 (p=0.0037), indicating a statistically significant reduction in the risk of death after adjusting for baseline risk factors [1] - Kaplan–Meier survival estimates indicated a median survival of 36.3 months for PrimeC compared to 21.4 months for the placebo group (log-rank p=0.0218) [1] Regulatory Engagement - NeuroSense is actively engaging with regulatory authorities to advance PrimeC towards potential marketing authorization, with preparations for a Phase 3 study underway [1]